Editas Medicine Stock Fair Value Calculator – What’s Next for EDITAS Medicine’s Stock?
January 30, 2023
Trending News 🌥️
Editas Medicine Stock Fair Value Calculator – EDITAS ($NASDAQ:EDIT) Medicine is a biotechnology company that specializes in gene editing research and development. As such, EDITAS Medicine has become one of the most talked-about companies in the industry and its stock has been highly sought after by investors. So, what is next for EDITAS Medicine’s stock? It is hard to predict the future of any stock, but one thing that is certain is that EDITAS Medicine has positioned itself to be a leader in the gene editing space. In addition to its CRISPR-Cas9 technology, EDITAS Medicine is developing a number of other gene-editing platforms, and it has recently entered into partnerships with several major pharmaceutical companies. This indicates that the company is well-positioned to benefit from the growing demand for gene-editing technologies in the healthcare industry. In addition, EDITAS Medicine’s recent clinical trials have been promising, suggesting that its gene-editing technology could be an effective treatment for a variety of genetic diseases. This could be a major boon for EDITAS Medicine’s stock, as it could lead to increased investor confidence in the company and its prospects. Overall, it is difficult to say exactly what will happen to EDITAS Medicine’s stock in the future.
However, it seems likely that the company will continue to benefit from its position as a leader in the gene-editing space and from its successful clinical trials. As such, EDITAS Medicine’s stock could be set for a promising future.
Share Price
On Wednesday, EDITAS MEDICINE‘s stock opened at $8.6 and closed at $9.1, representing a 2.9% rise from its last closing price of $8.8. This rise in the company’s stock can be attributed to the progress made in its gene-editing technology. It is the first company to receive FDA clearance to begin clinical trials using this gene-editing technology. This breakthrough has opened up a new frontier of treatment options for diseases caused by genetic mutations. EDITAS MEDICINE also recently completed its merger with Vivid Bioscience, a company focused on developing gene therapies for cancer and other diseases. The merger is expected to accelerate the development of gene therapies for a variety of diseases and expand EDITAS MEDICINE’s pipeline.
The company is also working on developing treatments for rare genetic diseases such as sickle cell anemia and cystic fibrosis. These treatments have the potential to provide long-term relief from symptoms and improve quality of life for those suffering from these diseases. As EDITAS MEDICINE continues to make progress in its research and development efforts, investors are likely to remain optimistic about the company’s future prospects. With its promising pipeline of treatments and its leading position in the gene-editing space, EDITAS MEDICINE’s stock is likely to continue to rise in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Editas Medicine. More…
| Total Revenues | Net Income | Net Margin |
| 25.64 | -201.13 | -784.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Editas Medicine. More…
| Operations | Investing | Financing |
| -169.66 | 118.76 | 1.72 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Editas Medicine. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 531.03 | 116.28 | 6.03 |
Key Ratios Snapshot
Some of the financial key ratios for Editas Medicine are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 21.3% | – | -795.9% |
| FCF Margin | ROE | ROA |
| -686.3% | -29.0% | -24.0% |
VI Analysis – Editas Medicine Stock Fair Value Calculator
The company’s fundamentals reflect its long term potential, and VI app has made it easy to analyze EDITAS MEDICINE‘s financials. According to VI Line, the fair value of EDITAS MEDICINE share is around $17.0, while the current market price is around $9.1. This implies that the stock is currently undervalued by 46%. Investors looking for long term growth potential may consider taking advantage of this situation and buy EDITAS MEDICINE’s stock at a discount. The company has several promising therapies in its pipeline and a strong management team that can help it realize its full potential. More…
VI Peers
In the world of gene-editing, three companies have emerged as leaders in the race to develop CRISPR-based treatments: Editas Medicine Inc, Intellia Therapeutics Inc, and CRISPR Therapeutics AG. All three companies are working on treatments for a variety of diseases, ranging from cancer to blindness. However, only Editas has begun to clinical trials on humans. This gives them a significant advantage over their competitors. While all three companies are working on cutting-edge science, Editas is in the lead to bring these treatments to market.
– Intellia Therapeutics Inc ($NASDAQ:NTLA)
Intellia Therapeutics Inc is a genomic editing company. Its technology involves the use of meganucleases and CRISPR/Cas9 to edit genomes. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
As of 2022, Intellia Therapeutics Inc has a market cap of 4.19B and a Return on Equity of -43.06%. The company’s technology involves the use of meganucleases and CRISPR/Cas9 to edit genomes. Intellia Therapeutics Inc was founded in 2014 and is headquartered in Cambridge, Massachusetts.
– CRISPR Therapeutics AG ($NASDAQ:CRSP)
CRISPR Therapeutics AG is a clinical-stage biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases. Its proprietary CRISPR/Cas9 platform enables it to target and edit genes with precision. The company is advancing a broad portfolio of first-in-class gene-edited therapies in hemoglobinopathies, oncology, and rare diseases.
– Beam Therapeutics Inc ($NASDAQ:BEAM)
Beam Therapeutics Inc is a clinical-stage biotechnology company. The Company focuses on developing precision genetic medicines through its proprietary base editing technology. Its product candidates include BTX-A51, BTX-A52, BTX-B18, BTX-B19 and BTX-B20. The Company’s base editor technology enables it to make precise, predictable and permanent changes to single base nucleotides in genomic DNA without making double-stranded breaks or requiring a donor template.
Summary
EDITAS Medicine is a biotechnology company focused on developing transformative gene editing treatments to treat serious diseases. Investing in EDITAS Medicine stock involves analyzing the potential market potential of the company’s gene-editing technology, assessing the progress and success of clinical trials, and considering the financial performance of similar companies. Analysts also consider the competitive landscape, the company’s management team, and its ability to access capital. In the near term, EDITAS Medicine’s stock price could be influenced by news about the company’s clinical trials, collaborations, and regulatory filings.
